NASDAQ: INSMInsmed Inc Stock
$95.80-2.65 (-2.69%)
Updated Jun 18, 2026
INSM Price
$95.80
Fair Value Price
N/A
Market Cap
$20.76B
52 Week Low
$90.39
52 Week High
$212.75
P/E
-16.69x
P/B
29.46x
P/S
42.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$819.56M
Earnings
-$1.18B
Gross Margin
81.8%
Operating Margin
-133.71%
Profit Margin
-144.4%
Debt to Equity
1.95
Operating Cash Flow
-$896M
Beta
1.01
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
INSM Overview
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INSM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INSM
Ranked#41 of 465
Ranked#41 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important INSM news, forecast changes, insider trades & much more!
INSM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INSM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INSM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INSM is poor value based on its book value relative to its share price (29.46x), compared to the US Biotechnology industry average (4.95x)
P/B vs Industry Valuation
INSM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INSM due diligence checks available for Premium users.
Valuation
INSM fair value
Fair Value of INSM stock based on Discounted Cash Flow (DCF)
Price
$95.80
Fair Value
-$153.86
Undervalued by
162.26%
INSM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INSM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.69x
Industry
15.77x
Market
9.47x
INSM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
29.46x
Industry
4.95x
INSM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INSM's financial health
Profit margin
Revenue
$306.0M
Net Income
-$163.6M
Profit Margin
-53.5%
INSM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INSM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.1B
Liabilities
$1.4B
Debt to equity
1.95
INSM's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INSM's short-term assets ($1.61B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INSM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INSM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$222.7M
Investing
$265.5M
Financing
$29.5M
INSM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INSM vs Biotech Stocks
Insmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.